Inactive Instrument

Aastrom Biosciences Inc Share Price Nasdaq

Equities

US00253U3059

Pharmaceuticals

End-of-day quote Nasdaq
- USD - Intraday chart for Aastrom Biosciences Inc
Sales 2024 * 239M 19.15B Sales 2025 * 299M 23.95B Capitalization 2.22B 178B
Net income 2024 * 4M 320M Net income 2025 * 25M 2B EV / Sales 2024 * 9.3 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 7.43 x
P/E ratio 2024 *
576 x
P/E ratio 2025 *
94.6 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.16%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 60 28/02/13
Director of Finance/CFO 49 24/01/21
Chief Operating Officer 62 09/04/17
Members of the board TitleAgeSince
Director/Board Member 63 05/01/15
Director/Board Member 67 05/01/15
Chairman 73 15/01/06
More insiders
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns.
Calendar
Related indices
More about the company